Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 ...

(“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

Cancer arises when your cells grow uncontrollably and refuse to die when they should. Normally, your body is equipped with regulatory processes to prevent this chaos. One such mechanism involves a ...

This review illustrates how the nuclear phosphoinositide-p53 signalosome integrates lipid signaling and p53 function to regulate cancer cell motility. The figure contrasts the tumor-suppressive ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

Toxicologists have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes. The gene coding for the ...

Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis. This is an ASCO Meeting Abstract from the 2024 ...

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...